increased (Greenwood & O'Grady 1975) . At the present time, for example, ampicillin resistant isolates of Escherichia coli account for more than 40% of all E. coli encountered in many urinary tract clinics. Furthermore, resistance has begun to appear in species other than E. coli (Lowbury et al. 1969) . Initially, this development seemed to affect primarily other enteric species but latterly there has been the dramatic appearance of penicillin resistance among some clinical isolates of Hemophilus influenzw and parainfluenzae (Farrar & O'Dell 1974 , Elwell et al. 1977 and also among gonococci (Phillips 1976 , Percival et al. 1976 , organisms which had been universally sensitive to penicillins up to that time.
Soon after the new penicillins were first introduced into clinical medicine, another class of penicillin-like molecules became available for therapeutic use. These antibiotics were the cephalosporins, molecules that shared the /3lactam nucleus of . the penicillins, but which otherwise had a distinct structure (Abraham & Loder 1972) . As was the case with methicillin and cloxacillin, these molecules had substantial degrees of resistance to staphylococcal penicillinase. However, unlike the two penicillins, the cephalosporins also proved very useful for the treatment of Gram negative infections.
Although the cephalosporins (notably cephalothin and cephaloridine) combined both anti-Gram positive and anti-Gram negative properties to a considerable extent, they did not completely escape the rise of resistant Gram negative infections. Whereas upwards of 40 % of all E. coli in most urinary tract clinics are currently ampicillin resistant, about half of these strains are resistant to cephalosporins of the cephalothin/ cephaloridine type as well (as will be described in this Symposium).
Penicillin resistance, when it occurs among Gram positive bacterial species, is almost universally due to the production of a penicillin destroying enzyme (Richmond et al. 1964 ). Among resistant Gram negative isolates, the situation is less clear cut. Many Gram negative bacteria are naturally insensitive to penicillins and cephalosporins; that is, their resistance is not primarily due to the production of a penicillin or cephalosporin destroying enzyme. Blut equally large amounts of penicillinase are produced by many resistant species (Jack & Richmond 1970 The Problem ofResistance In the early years of penicillin use, it was penicillinase producing isolates of Staphylococcus aureus which posed many problems. From a position in which penicillin resistant S. aureus strains were barely detectable when benzyl penicillin was first used therapeutically, the incidence of resistant isolates in hospitals rose to reach values of about 75% by the end of the 1950s (Munch-Petersen & Boundy 1962) .
This challenge from penicillinase producing S. aureus strains was met partly by developments in the management of patients (more sophisticated cross-infection control, for example) and partly by the introduction of a new range of penicillin antibiotics which were resistant to hydrolysis by the enzyme which conferred resistance to the old penicillins (Rolinson et al. 1960) . Thus, clinical efficacy was regained by designing novel penicillin derivatives which were resistant to penicillinase attack.
Soon after these so-called new penicillinsnotably methicillin and cloxacillin (Rolinson & Sutherland 1973 ) -became available in the early 1960s a change came over the clinical scene. The penicillinase producing Staphylococci which had been a considerable scourge up to that time decreased in relative importance in the clinic, and Gram negative bacteria started to appear in disturbing numbers. To meet this new challenge, a new penicillinampicillinwas designed and proved widely effective.
It has never been satisfactorily established whether this populational change from Gram positive to Gram negative predominance was due primarily to the impact of the new penicillins on the staphylococcal population in hospitals, or whether the invention and use of ampicillin in the clinic affected the incidence of Gram negative bacteria directly. Whatever the reason, however, the troublesome problems in the hospitals tended, from this time on, to concern Gram negative infections, a change that was very dramatic in its impact.
Unfortunately, the respite given by the advent of ampicillin has not persisted. Although Gram negative bacteria in domiciliary practice tended to remain (and for that matter still remain) predominantly sensitive, the incidence of ampicillin resistance among hospital strains has slowly penicillin and cephalosporin destroying enzymes found in clinical isolates of Gram negative bacteria revealed a situation much more complex than that found in S. aureus (Jack & Richmond 1970) . Whereas all Staphylococci normally produce a single type of penicillin destroying enzyme (Richmond et al. 1964 ), a wide range of different enzymes can be found in various Gram negative species. Moreover, the same enzyme is not always characteristic of a given bacterial species among Gram negative organisms. Nor can one be sure that such bacteria only produce a single type of enzyme (Jack & Richmond 1970) .
This wide variety in the nature of penicillin and cephalosporin destroying enzymes in Gram negative bacteria has posed a daunting problem to those who would try to develop new cephalosporins resistant to the action of all the enzymes found in Gram negative bacteria. Since such a wide range of different activities, sometimes comprising both penicillins and cephalosporins, is to be found, the new cephalosporins would have to have a much more secure and wideranging resistance to enzymes from Gram negative bacteria than the new penicillins for use against clinical isolates of S. aureus required.
In the event, recent developments have produced a number of novel cephalosporins designed to replace cephalothin and cephaloridine, and some are more resistant to enzymic hydrolysis than others. The present paper considers this feature of the new cephalosporins, with particular reference to cefuroxime.
The Enzymes
In the early surveys on the ,B-lactamase enzymes that degraded penicillins and/or cephalosporins and that were to be found in Gram negative bacteria of clinical origin, about 15 distinct types of enzyme were detected (Jack & Richmond 1970) . The substrate profiles of these enzymes ranged from those with an almost exclusive activity against cephalosporins in the one hand, to those that were predominantly active against penicillins on the other. Latterly, a more detailed analysis of the data, and further investigations, has suggested that the number may be considerably higher (Sykes & Matthew 1976) . Under these circumstances, therefore, it becomes important to try to establish whether a limited number of basic profiles are to be found among this large collection of enzymes, even if it is only to facilitate the job of the researcher to evaluate new compounds.
In practice, the profiles found amongst these enzymes reduce to three classes: first, those with predominant activity against cephalosporins (e.g. Type la); secondly, those with activity against both penicillins and cephalosporins, including cloxacillin (e.g. Type IVc); and thirdly, those with activity against both penicillins and cephalosporins but which are inhibited by cloxacillin (e.g. Type Illa). To what extent this classification reflects an underlying molecular distinction between these enzymes is, as yet, unclear. These profiles are summarized in Table 1 .
The fact that one can reduce the large number of different enzymic hydrolysis patterns to 3 basic types without doing too much over-simplification allows one to assess the properties of new penicillins and cephalosporins with some ease and precision. In practice, this is done with the help of simple assays in a spectrophotometer at wavelengths that allow one to detect the enzymic attack that ruptures the fl-lactam bond of the antibiotic, a link vital for activity in both penicillins and cephalosporins (Ross & O'Callaghan 1975) .
The New Cephalosporins The cephalosporins available for clinical use up to now have all been significantly susceptible to destruction by one or other of the enzymes to be found among Gram negative bacteria of clinical origin. This range of compounds extends to cephalothin, cephaloridine, cephalexin, cephradine, cephracetrile and cefazolin (Richmond & Wotton 1976) . This information is summarized in Table 2 . In all cases substantial hydrolysis is detectable with at least one enzyme. These cephalosporins cannot therefore be expected to be active against all ,B-lactamase producing strains of enteric bacteria. This is largely found to be the case in practice. It is important to note that even the most recent addition to the above list (cefazolin, Nishida et al. 1970) is not resistant to f-lactamase attack, something that must mitigate the positive properties that this compound exhibits in terms of its inherent antibacterial Richmond & Wotton 1976) activity against sensitive strains and the high blood levels achieved following intravenous injection.
In addition to the cephalosporins mentioned in Table 2 , there are 3 compounds from this group of antibiotics which have been much discussed recently and which are on the point of entering the market at the time of writing. These compounds are cephamandole (Wick & Preston 1972), cefoxitin (Wallick & Hendlin 1974 ) and cefuroxime . All these 3 compounds possess features which suggest that they may have advantages over the injectible cephalosporins already available in the clinic. Only 2 of these molecules however, are resistant to ,-lactamase attack: cefoxitin (Onishi et al. 1974 ) and cefuroxime (as described in this Symposium, Table 3 ). Cefamandole, although resistant to the cephalosporinases of Class I, nevertheless is significantly hydrolyzed by the enzymes which have a broad action profile which includes cloxacillin as a substrate (Richmond & Wotton 1976) .
Cefoxitin is an example of a special class of cephalosporins: the 7-methoxy cephalosporins, or cephamycins. Cefuroxime, on the other hand, has a hydrogen atom in the 7 position.
In practice, it emerges that the insertion of a methoxy group in the 7 position ofa cephalosporin very frequently renders the compound insenitive to all the ,-lactamases yet encountered among clinical isolates. Indeed, so resistant is this class of molecule to enzymic hydrolysis in general that it is hard to detect destruction at all. Even after overnight incubation in the presence of many bacterial strains that produce penicillinase, destruction of cefoxitin is barely detectable (Onishi et al. 1974 ). This compound then has a high degree of ,B-lactamase resistance. Only about 5 % or less of ampicillin-resistant strains of E. coli from the clinic are resistant to cefoxitin.
Cefuroxime shares with cefoxitin a very high degree of resistance to all the fl-lactamases found in clinical isolates, even though it is not a 7methoxy derivative, and it is similarly effective against 3-lactamase producing bacteria (this Symposium). It is possible to detect a very low rate of hydrolysis of cefuroxime by both the broad spectrum ,B-lactamases (Richmond & Wotton 1976) . However, the measured rate of hydrolysis is less than 1 % of that found with cephaloridine. Put in other terms, this means that a given amount of antibacterial activity, present in the patient as cephaloridine or cephalothin, would be half destroyed within 1 h, whereas an analogous amount of activity present as cefuroxime would only be half destroyed after more than 4 days. In the light of this calculation, the stability of cefuroxime is ample to ensure its survival for long enough to cover the period from injection to elimination in man. In a sense, therefore, cefoxitin exhibits a degree of over-kill as far as ,B-lactamase stability is concerned, although this is not a significant disadvantage.
Conclusion
The increasing incidence of the ,B-lactamase producing resistant clinical isolates of enteric bacteria has put a premium on the development of /3-lactamase resistant derivatives of cephalosporins. At present two are about to become available for therapeutic use, cefuroxime and cefoxitin. In practice, both are effectively resistant to hydrolysis by all the ,B-lactamases likely to be encountered in clinical isolates of enteric bacteria. The compounds may have various particular advantages and disadvantages. From the point of view of their response to /3-lactamase attack, they are both insensitive.
Professor C S Goodwin (Perth) asked the Chairman whether he had found any Gram negative organisms that destroyed cefuroxime. They had discovered an Escherichia coli which destroyed it without difficulty.
Professor Richmiond (Chairman) said that he and Glaxo workers had examined Professor Goodwin's strain and it certainly did destroy cefuroxime.
Another organism which did so was Bacteroides fragilis where the enzyme if present (and it was not present in all strains) would hydrolyze cefuroxime as well.
Dr C H O'Callaghan (Greenford) said that they had examined many strains from various parts of the world and there were undoubtedly some which would destroy cefuroxime, but the one which Professor Goodwin had found in Harrow seemed unique of its kind. It looked like an ordinary Escherichia coli and as far as they could tell from isoelectric focusing, the enzyme was chromosomally mediated.
The Chairman had classified enzymes into groups but because there were 5 major groups it would be a mistake to believe that there were only 5 kinds of ,-lactamase. Isoelectric focusing had now distinguished more than 40. However, a study in Nottingham had shown that most of these each contained 2 or 3 types. The Type Illa accounted for perhaps 50 %. Others might occur in less than I % of isolates. Workers had to beware of concentrating on the oddities and overlooking those forms that occurred most of the time.
Professor Richmond (Chairman) said that there were also organisms which would destroy cefoxitin and so one must expect that even this lactam link would be destroyed by the enzymes in time. The interesting question was whether this would have clinical importance.
Dr A Percival (Liverpool) had looked at 100 strains of Bacteroidesfragilis and every strain had a constitutive ,B-lactamase which inactivated cefuroxime. In 60% of strains it was present only in small amounts but the MIC values were high. In 40 %, there was a second, inducible enzyme which was even more active. Cefuroxime was susceptible to the common clinical isolates of B. fragili. but cefoxitin, in contrast, was not. Of all the cephalosporins so far tested that was the only one completely stable to the innate, universally pre.;ent ,B-lactamase of B. fragilis. The enzymes were common in other species too, but they did not occur in B. fusiformis.
Dr Gaya asked Dr Scott how many infections in his series were bacterxmic, i.e. confined to blood culture, and what his success rate had been in bacteremic infections. Dr Scott said that he had one case which had been a clinical failure. This was a woman with acute cholecystitis who developed an E. coli septicemia.
Blood cultures were negative as long as she was on cefuroxime, but they became positive again when she stopped and she had to be treated with gentamicin.
Dr C Thornsberry, returning to the question of enterobacterial pathogens and cephalosporins, said that some organisms appeared to be totally inhibited at a particular concentration so that one would describe them as sensitive. After a while, however, they began growing again, and he wondered if a successful clinical outcome could be obtained in treating an infection with this kind of organism.
Cefuroxime
Dr Sabath said the phenomenon seemed comparable to Dr Barry's description of an increase in MIC after exposure of a variety of organisms to some cephalosporins. He did not know whether this was due to enzyme induction or selection of organisms with greater permeability barriers to the antibiotic. It was obviously an important observation but to describe its clinical significance one would have to correlate clinical outcome with infection due to this type of organism. However, if adequate testing were not done beforehand no such correlation could be established so it was appropriate that Dr Thornsberry had raised the point.
Professor C S Goodwin (Perth) said that cefuroxime might produce filamentous forms at active concentrations and that it might be necessary to increase the concentration to obtain a bactericidal effect. He felt that, as with cefazolin when it was first introduced, the MIC and serum level of cefuroxime might be too low. He had found that when it was given in higher doses, much better clinical results were obtained.
The body could get rid of filamentous forms but in looking at clinical results with respect to concentration, one also had to take protein binding into account.
Dr Sabath said that the problem of therapy for bacterial infections was becoming more interesting because of the recognition (certainly among the ,B-lactam antibiotics) that different drugs affected the bacteria in different ways. One had to consider interplay with the host defences, and there was some spontaneous recovery from infection. There was much that they did not know, but it seemed probable that virtually all classes of antibiotics had effects on bacteria at subinhibitory concentrations which changed their ability to be phagocytosed by the host defences. Because of this interplay, it may indeed be necessary to have increased dosages.
However, the possibility also existed (if only in bacterial endocarditis) that extremely high concentrations might actually be harmful because of the paradoxical effects first described by Garrard in 1944, but usually attributed to Eagle in 1947.
Professor G S M Kellaway (Auckland) asked if anyone had used doses of cefuroxime greater than Dr Scott's and was able to decide whether liver enzyme disturbances were related to dose.
Dr R Norrby (Gothenburg) said that in 90 patients he had seen 21 cases of increased liver transaminases.The effect was certainly not dose related.
Dr C H O'Callaghan (Greenford) concluded by returning to, Professor Goodwin's point about serum. In establishing whether antibiotics were serum bound she used untreated serum, but serum used to establish the MIC of Gram negative organisms must be heated otherwise they would not grow. This made it very difficult to establish the effect of the antibiotic. If one tried to remove the effect by dilution, one also affected the serum binding.
With Gram negative organisms, however, there did appear to be a factor in serum which could not be readily measured in vitro and which might account for the good results in the mouse protection test with organisms where the MIC in ordinary media made the possibility of a therapeutically successful outcome very unlikely. There was continual failure to make the bacteria grow if the serum was not first inactivated. But the patient's circulating serum had not been inactivated. It was difficult to establish how this would influence the activity of the antibiotic.
